Cargando…
Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial
Metformin, the first-line therapy for type 2 diabetes (T2D), decreases hepatic glucose production and reduces fasting plasma glucose levels. Dorzagliatin, a dual-acting orally bioavailable glucokinase activator targeting both the pancreas and liver glucokinase, decreases postprandial glucose in pati...
Ejemplares similares
-
Effect of renal impairment on the pharmacokinetics and safety of dorzagliatin, a novel dual‐acting glucokinase activator
por: Miao, Jia, et al.
Publicado: (2021) -
Population Pharmacokinetic Analysis of Dorzagliatin in Healthy Subjects and Patients with Type 2 Diabetes Mellitus
por: Wang, Kun, et al.
Publicado: (2023) -
A phase I open-label clinical trial to study drug-drug interactions of Dorzagliatin and Sitagliptin in patients with type 2 diabetes and obesity
por: Chen, Li, et al.
Publicado: (2023) -
Characterization of bHLH/HLH genes that are involved in brassinosteroid (BR) signaling in fiber development of cotton (Gossypium hirsutum)
por: Lu, Rui, et al.
Publicado: (2018) -
MicroRNA-124 promotes hepatic triglyceride accumulation through targeting tribbles homolog 3
por: Liu, Xing, et al.
Publicado: (2016)